Monoclonal Antibodies in Multiple Sclerosis Treatment Publisher



Moeinafshar A^{1, 2} ; Rezaei N^{2, 3, 4} Show Affiliations
Source: Translational Neuroimmunology: Multiple Sclerosis: Volume 8 Published:2023

Abstract

Multiple sclerosis (MS) is one of the common neurological disorders, with approximately 2.5 million confirmed cases worldwide. Its incidence, as a result of predisposal to etiological factors, is mostly due to immunological reactions in the central nervous system. Monoclonal antibodies are important agents used to specifically target immune modulatory molecules. Since these substances show a low incidence of serious adverse effects, exert promising effects on reducing the relapse rate and the number of lesions, which can be detected through magnetic resonance imaging (MRI), and show an improvement in the disability evaluation criteria, they are both safe and efficient drugs. Targeted therapy is of great importance in autoimmune diseases such as MS. The targeting nature of monoclonal antibody therapies allows physicians to reach more predictable outcomes with less off-target adverse effects. A variety of these agents have been approved by the FDA and are widely used, though more studies are needed to improve the safety and efficacy of these novel approaches. In this review, a brief explanation of MS and data on the mechanistic basis, safety, and efficacy of monoclonal antibodies in MS patients are provided. © 2023 Elsevier Inc. All rights reserved.